{"id":"placebo-for-lofexidine","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebos are inert substances used as controls in clinical trials or, in some cases, as therapeutic interventions that rely on patient expectation and psychological mechanisms. In this context, it serves as a comparator to lofexidine, an alpha-2 adrenergic agonist used in opioid withdrawal management. The placebo arm allows assessment of lofexidine's efficacy independent of expectation effects.","oneSentence":"A placebo contains no active pharmaceutical ingredient and produces therapeutic effects solely through the placebo effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:00:54.806Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in clinical trials for opioid withdrawal management (comparator to lofexidine)"}]},"trialDetails":[{"nctId":"NCT05995535","phase":"PHASE2","title":"Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2024-01-01","conditions":"Opiate Withdrawal Syndrome, Opioid Use","enrollment":150},{"nctId":"NCT04325659","phase":"PHASE2, PHASE3","title":"An Innovative Intervention for OUD Treatment","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2020-11-15","conditions":"Opioid-Related Disorders, Opioid Dependence, Opioid Addiction","enrollment":46},{"nctId":"NCT05712707","phase":"PHASE1, PHASE2","title":"Sublingual Dexmedetomidine for Treating Opioid Withdrawal","status":"ACTIVE_NOT_RECRUITING","sponsor":"New York State Psychiatric Institute","startDate":"2023-02-28","conditions":"Opioid Use Disorder, Opioid Withdrawal","enrollment":160},{"nctId":"NCT05053503","phase":"NA","title":"Delivering Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention in Opioid Use Disorder","status":"COMPLETED","sponsor":"Spark Biomedical, Inc.","startDate":"2022-05-27","conditions":"Opioid-use Disorder, Opioid Withdrawal","enrollment":108},{"nctId":"NCT04360681","phase":"PHASE2","title":"Lofexidine Combined With Buprenorphine for Reducing Symptoms of PTSD and OU Relapse in Veterans","status":"RECRUITING","sponsor":"Pharmacotherapies for Alcohol and Substance Use Disorders Alliance","startDate":"2021-03-09","conditions":"Post Traumatic Stress Disorder, Opioid-use Disorder","enrollment":120},{"nctId":"NCT03718065","phase":"PHASE2","title":"Impact of Lofexidine on Stress, Craving and Opioid Use","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2019-06-26","conditions":"Opioid-use Disorder, Opiate Dependence","enrollment":112},{"nctId":"NCT04218240","phase":"PHASE2","title":"Combining Pregabalin (LYRICA®) With Lofexidine (LUCEMYRATM) to Treat OPIOID Withdrawal","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2020-12-17","conditions":"Opioid Withdrawal","enrollment":90},{"nctId":"NCT01863186","phase":"PHASE3","title":"Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal","status":"COMPLETED","sponsor":"USWM, LLC (dba US WorldMeds)","startDate":"2013-06","conditions":"Opioid Dependence, Acute Opioid Withdrawal Syndrome","enrollment":603},{"nctId":"NCT01020019","phase":"PHASE2, PHASE3","title":"Combined Pharmacotherapy for Cannabis Dependency","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2010-01","conditions":"Cannabis Dependence, Marijuana Dependence","enrollment":156},{"nctId":"NCT01820442","phase":"PHASE1","title":"Pharmacokinetic & Pharmacodynamic Interaction of Lofexidine and Buprenorphine in Buprenorphine Maintained Patients","status":"COMPLETED","sponsor":"USWM, LLC (dba US WorldMeds)","startDate":"2013-03","conditions":"Opioid Dependence, Buprenorphine Withdrawal Syndrome","enrollment":30},{"nctId":"NCT01650649","phase":"PHASE1","title":"Main Study of Lofexidine and Methadone Pharmacodynamic Interaction in Methadone Maintained Patients","status":"COMPLETED","sponsor":"USWM, LLC (dba US WorldMeds)","startDate":"2012-07","conditions":"Opioid Dependence, Methadone Withdrawal Syndrome","enrollment":27},{"nctId":"NCT00032942","phase":"PHASE3","title":"Lofexidine for Opiate Withdrawal - 1","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2001-04","conditions":"Opioid-Related Disorders","enrollment":66},{"nctId":"NCT01675648","phase":"PHASE4","title":"Lofexidine for Inpatient Opiate Detox in Singapore","status":"COMPLETED","sponsor":"Institute of Mental Health, Singapore","startDate":"2012-08","conditions":"Opiate Dependent Patients Who Are Undergoing Inpatient Detoxification in Singapore","enrollment":112},{"nctId":"NCT00142909","phase":"PHASE2","title":"Effectiveness of Lofexidine to Prevent Stress-Related Opiate Relapse During Naltrexone Treatment - 1","status":"COMPLETED","sponsor":"Yale University","startDate":"2005-02","conditions":"Opioid-Related Disorders","enrollment":86},{"nctId":"NCT00235729","phase":"PHASE3","title":"Lofexidine for Inpatient Opiate Detox","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"2006-06","conditions":"Opiate Addiction","enrollment":264}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":49,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo for Lofexidine","genericName":"Placebo for Lofexidine","companyName":"Institute of Mental Health, Singapore","companyId":"institute-of-mental-health-singapore","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A placebo contains no active pharmaceutical ingredient and produces therapeutic effects solely through the placebo effect. Used for Control arm in clinical trials for opioid withdrawal management (comparator to lofexidine).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}